Ryan C. Massa, MD

Tuteja S, Cayabyab MAS, Hoffecker G, Varughese LA, de Dieu Ndayishimiye J, Wittner VA, Wang X, Hatch R, Capozzi D, Harr M, Santani A, Hakonarson H, Watson D, Gabriel P, Doucette A, Massa R, Damjanov N, Reddy N, Oyer R, Teitelbaum UR. Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial , JCO Precis Oncol, 9: 2025,e2500086.

Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, Rush E, Karunamurthy A, Massa RC, Rohatgi A, Workman CJ, Kirkwood JM, Bruno TC, Vignali DAA. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity , Cell, 187(16): 2024,4373-4388

Eads JR, Graham N, Gibson MK, Rajdev L, Chakravarthy AB, Khullar OV, Lin SH, Wistuba II, Agarwal R, Blazar M, Mehta DR, Al Baghdadi T, Jin N, Massa RC, Hamilton SR, Staley CA, Wong TZ, O'Dwyer PJ. A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). , J Clin Oncol, American Society of Clinical Oncology Annual Meeting, Chicago, IL., 42: 2024,(suppl 16; abstr 4000)

Karapetya L, Karunamurthy A, Cillo A, Wang S, Massa RC, Rohatgi A, Deitrick C, Najjar YG, Davar D, Luke JJ, Sander C, Rose A, Rush E, Joy M, Kunning S, Bao R, Wang H, Bruno TC, Vignali DD, Kirkwood JM Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel) , J Clin Oncol, American Society of Clinical Oncology Annual Meeting, Chicago, IL. , 42: 2024,(suppl 16; abstr 9525)

Tuteja S, Cayabyab MA, Hoffecker G, Varughese L, Wittner V, Ndayishmiye JDD, , Wang X, Harr M, Santani A, Hakonarson H, Massa RC, Damjanov N, Reddy NJ, Oyer RA, Teitelbaum UR Implementing DPYD/UGT1A1 testing to prevent treatment related adverse events (TRAE) in patients with gastrointestinal (GI) cancer: Results of a pragmatic implementation trial , J Clin Oncol, American Society of Clinical Oncology Annual Meeting, Chicago, IL. , 42: 2024,(suppl 16; abstr 10599)

Eads J, Chapin W, Massa R Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers , Advances in Oncology, 4(1): 2024,p207-218

Karasic TB, Brown TJ, Schneider C, Teitelbaum UR, Reiss KA, Mitchell TC, Massa RC, O'Hara MH, DiCicco L, Garcia-Marcano L, Amaravadi RK, O'Dwyer PJ. Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer , Oncologist, 27(9): 2022,716-e689

Reiss KA, Mick R, Teitelbaum U, O'Hara M, Schneider C, Massa R, Karasic T, Tondon R, Onyiah C, Gosselin MK, Donze A, Domchek SM, Vonderheide RH. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial , Lancet Oncol, 23(8): 2022,1009-1020.

Brown TJ, Massa RC. Challenges in the Management of Patients With HER2-Amplified Colorectal Cancer , JCO Oncol Pract, 18(8): 2022,555-556

Varughese LA, Bhupathiraju M, Hoffecker G, Terek S, Harr M, Hakonarson H, Cambareri C, Marini J, Landgraf J, Chen J, Kanter G, Lau-Min KS, Massa RC, Damjanov N, Reddy NJ, Oyer RA, Teitelbaum UR, Tuteja S. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing , Front Oncol, 12: 2022,859846